Clinical trial
Torch: A Phase II Study to Determine the Safety and Efficacy of the Dual mTORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
NCT02752204 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Torch: A Phase II Study to Determine the Safety and Efficacy of the Dual mTORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Lead sponsor
- University of Birmingham
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2015
- Completion date
- February 6, 2020
- Enrollment
- 36 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse large b-cell lymphoma